Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02175004
Other study ID # ISIS 420915-CS3
Secondary ID 2013-004561-13
Status Completed
Phase Phase 3
First received
Last updated
Start date June 26, 2014
Est. completion date January 7, 2021

Study information

Verified date November 2023
Source Ionis Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the safety and tolerability of extended dosing with IONIS-TTR Rx in patients with Familial Amyloid Polyneuropathy.


Description:

Familial Amyloid Polyneuropathy (FAP) is a rare, hereditary disease caused by mutations in the transthyretin (TTR) protein. TTR is made by the liver and secreted into the blood. TTR mutations cause it to misfold and deposit in multiple organs causing FAP. IONIS-TTR Rx is an antisense drug that is designed to decrease the amount of mutant and normal TTR made by the liver. It is predicted that decreasing the amount of TTR protein will result in a decrease in the formation of TTR deposits, and thus slow or stop disease progression. This study evaluates the safety and tolerability of extended dosing with IONIS-TTR Rx in patients with Familial Amyloid Polyneuropathy.


Recruitment information / eligibility

Status Completed
Enrollment 135
Est. completion date January 7, 2021
Est. primary completion date September 11, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Satisfactory completion of dosing & efficacy assessments in ISIS 420915-CS2 Exclusion Criteria: - Any new condition or worsening of existing condition that could make the patient unsuitable for participation, or interfere with the patient participating in and/or completing the study

Study Design


Intervention

Drug:
Inotersen
Inotersen SC

Locations

Country Name City State
Argentina FLENI Buenos Aires
Brazil Federal University of Rio de Janeiro - University Hospital Rio de Janeiro
Brazil AACD Sao Paulo
France CHU Henri Mondor - Department of Neurology Creteil
France CHU Bicetre Aphp French Referral Center for FAP/Cornamyl Network Le Kremlin Bicetre
Germany UKM; Universitätsklinikum Münster, Klinik für Transplantationsmedizin Munster
Italy Universita Degli Studi Di Messina - Azienda Ospedaliera Universitaria Policlinico "Gaetano Martino" Messina Sicily
Italy Centro per lo Studio e la Cura delle Amiloidosi Sistemiche - Fondazione IRCCS Policlinico San Matteo Pavia
Portugal CHLN - Hospital de Santa Maria Lisbon
Portugal CHP-HGSA, Unidade Clinica de Paramiloidose Porto
Spain Hospital Clinic Barcelona
Spain Hospital Universitari Vall D' Hebron Barcelona
United Kingdom University College London - National Amyloidosis Centre London
United States Johns Hopkins University Bayview Medical Center Baltimore Maryland
United States Boston University School of Medicine - Amyloid Treatment & Research Program Boston Massachusetts
United States Indiana University School of Medicine Indianapolis Indiana
United States Columbia University Medical Center - The Neurological Institute New York New York
United States Mount Sinai Medical Center New York New York
United States University of California, Irvine Orange California
United States Penn Presbyterian Medical Center Philadelphia Pennsylvania
United States Oregon Health & Science University Portland Oregon
United States Mayo Clinic Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Ionis Pharmaceuticals, Inc.

Countries where clinical trial is conducted

United States,  Argentina,  Brazil,  France,  Germany,  Italy,  Portugal,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Related to Study Drug An adverse event (AE) is any unfavorable and unintended sign (including a clinically significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE is considered related to the investigational drug product. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. An SAE is any untoward medical occurrence that at any dose that results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect, or is an important medical event. TEAEs considered related to the study drug as assessed by the Investigator are reported. From first dose of study drug up to 3 months post treatment period of 260 weeks (Up to approximately 272 weeks)
Primary Percentage of Participants With Change From Baseline in Vital Signs Vital signs included blood pressure, heart rate, respiratory rate, and temperature. Only categories with at least one participant with event are reported. From first dose of study drug up to 3 months post treatment period of 260 weeks (Up to approximately 272 weeks)
Primary Percentage of Participants With Change From Baseline in Weight As prespecified in the protocol, percentage of participants with change from baseline in weight is reported in 2 categories, decrease of =7% from Baseline and increase of =7% from Baseline. From first dose of study drug up to 3 months post treatment period of 260 weeks (Up to approximately 272 weeks)
Primary Percentage of Participants With Clinically Significant Change From Baseline in Laboratory Test Values Clinical laboratory tests included the analysis of chemistry, haematology, and urinalysis. Any value outside the normal range will be flagged for the attention of the investigator who will assess whether or not a flagged value is of clinical significance. Only those categories with at least one participant with event are reported. Normal range of creatinine clearance is 110 to 150 mL/min in males and 100 to 130 mL/min in females. Normal urine protein to creatinine (P/C) ratio= <0.2. Normal range for Alanine Aminotransferase (ALT) is 4 to 36 units per liter (U/L). Platelets normal range=140×10^9/L to 400×10^9/L. From first dose of study drug up to 3 months post treatment period of 260 weeks (Up to approximately 272 weeks)
Primary Percentage of Participants With Change From Baseline in QT Interval Corrected Using Fridericia's Formula (QTcF) as Determined by Electrocardiogram (ECG) Normal QTcF at Baseline is defined as =450 milliseconds (ms) for males or =470 ms for females. Percentage of participants with QT interval outside of normal range are reported. From first dose of study drug up to 3 months post treatment period of 260 weeks (Up to approximately 272 weeks)
Primary Percentage of Participants Using Concomitant Medication for Nervous and Cardiovascular System Disorders A concomitant therapy was any non-protocol-specified drug or substance (including over-the counter medications, herbal medications, and vitamin supplements) administered between signing of informed consent and the final post-treatment visit for treating nervous and cardiovascular system disorders. From first dose of study drug up to 3 months post treatment period of 260 weeks (Up to approximately 272 weeks)
Primary Percentage of Participants With Change From Baseline in Ophthalmic Examination as Assessed by Visual Acuity Changes From first dose of study drug up to 3 months post treatment period of 260 weeks (Up to approximately 272 weeks)
Primary Percentage of Participants With Change From Baseline in Light Detection Ability Measured by Electroretinography Baseline (Baseline is the Baseline of the Previous Study- Study CS2), Weeks 78 and 156
Secondary Change From Baseline in the Modified Neuropathy Impairment Score (mNIS)+7 Composite Score at Weeks 78 and 156 The mNIS+7 composite score is a measure of neurologic impairment that evaluates muscle weakness, sensation, reflexes, nerve conduction, and autonomic function. The mNIS+7 Composite Score has a range of -22.32 to 346.32 and a higher mNIS+7 composite score indicates worsening disease. A positive change from Baseline indicates worsening of polyneuropathy impairments. Mixed Effects Model with Repeated Measures (MMRM) was used for the analysis. Baseline (Baseline is the Baseline of the Previous Study- Study CS2), Weeks 78 and 156
Secondary Change From Baseline in the mNIS +7 Component: Heart Rate to Deep Breathing Score at Weeks 78 and 156 Heart rate to deep breathing is a quantitative autonomic test using the CASE IV instrument that measures a participant's change in heart rate after deep breathing. The score of this component ranges from 0 to 3.72 points. Higher scores indicate impairment. MMRM was used for the analysis. Baseline (Baseline is the Baseline of the Previous Study- Study CS2), Weeks 78 and 156
Secondary Change From Baseline in the mNIS +7 Component: Nerve Conduction Score at Weeks 78 and 156 The nerve conduction tests are quantitative tests that measure the conduction attributes of preselected nerves. The score range of this component is 0 to 18.6 points. Higher scores indicate impairment. MMRM was used for the analysis. Baseline (Baseline is the Baseline of the Previous Study- Study CS2), Weeks 78 and 156
Secondary Change From Baseline in the mNIS +7 Component: Heat-Pain Sensory Score at Weeks 78 and 156 The Heat-Pain Sensory test uses the CASE IV instrument to perform standardized psychophysical measurement to determine pain sensory thresholds in response to heat. The maximum score of this component is 0 to 40 points. Higher scores indicate impairment. MMRM was used for the analysis. Baseline (Baseline is the Baseline of the Previous Study- Study CS2), Weeks 78 and 156
Secondary Change From Baseline in the mNIS +7 Component: Touch-Pressure Sensory Score at Weeks 78 and 156 The Touch-Pressure Sensory test uses the CASE IV instrument to perform standardized psychophysical measurement to determine pressure sensory thresholds in response to touch. The score range of this component is 0 to 40 points. Higher scores indicate impairment. MMRM was used for the analysis. Baseline (Baseline is the Baseline of the Previous Study- Study CS2), Weeks 78 and 156
Secondary Change From Baseline in the Neuropathy Impairment (NIS) Composite Score at Week 52 of Years 4 and 5 The NIS score is a measure of neurologic impairment. The NIS Score has a range of 0 to 244 and a higher NIS score indicates lower function. A positive change from Baseline indicates worsening. MMRM was used for the analysis. Baseline (Baseline is the Baseline of the Previous Study- Study CS2), Week 52 of Years 4 and 5
Secondary Change From Baseline in the NIS Component: Cranial Nerves Score at Week 52 of Years 4 and 5 Cranial Nerve assessment involves testing 3rd and 6th nerves and facial, palate, and tongue weakness. The score range for this component is 0 to 40 points. Higher scores indicate worsening. MMRM was used for the analysis. Baseline (Baseline is the Baseline of the Previous Study- Study CS2), Week 52 of Years 4 and 5
Secondary Change From Baseline in the NIS Component: Muscle Weakness Score at Week 52 of Years 4 and 5 Muscle weakness involves testing 19 movements of muscles. The score range of this component is 0 to 152 points. Higher scores indicate worsening. MMRM was used for the analysis. Baseline (Baseline is the Baseline of the Previous Study- Study CS2), Week 52 of Years 4 and 5
Secondary Change From Baseline in the NIS Component: Reflexes Score at Week 52 of Years 4 and 5 The Reflexes Score involves testing 5 reflexes to stimuli. The score range of this component is 0 to 20 points. Higher scores indicate worsening. MMRM was used for the analysis. Baseline (Baseline is the Baseline of the Previous Study- Study CS2), Week 52 of Years 4 and 5
Secondary Change From Baseline in the NIS Component: Sensory Score at Week 52 of Years 4 and 5 The Sensory Score is based on testing an index finger and a big toe each to 4 stimuli. The score of this component ranges from 0 to 32 points. Higher scores indicate impairment. MMRM was used for the analysis. Baseline (Baseline is the Baseline of the Previous Study- Study CS2), Week 52 of Years 4 and 5
Secondary Change From Baseline in the Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN) Questionnaire Total Score at Weeks 78 and 156 The Norfolk QoL-DN score is a measure of physical function/large fiber neuropathy, symptoms, activities of daily living, small fiber neuropathy, and autonomic neuropathy. The Norfolk QoL-DN total score has a range of -4 to 136, and a higher Norfolk QoL-DN score indicates poorer QoL. A positive change from Baseline indicates worsening in the QoL. MMRM was used for the analysis. Baseline (Baseline is the Baseline of the Previous Study- Study CS2), Weeks 78 and 156 and at the end of each subsequent treatment year (Week 52 of Years 4 and 5)
Secondary Change From Baseline in the Norfolk QoL-DN Physical Functioning/Large Fiber Neuropathy Domain Score The Norfolk QoL-DN physical functioning/large fiber neuropathy domain score is a sub-score of the total Norfolk QoL-DN Questionnaire. The Norfolk QoL-DN physical function/large fiber neuropathy domain score has a range of -4 to 56, and a higher Norfolk QoL-DN domain score indicates poorer quality of life (QoL). A positive change from Baseline indicates worsening in the QoL. MMRM was used for the analysis. Baseline (Baseline is the Baseline of the Previous Study- Study CS2), Weeks 78 and 156 and at the Week 52 of Year 4
Secondary Change From Baseline in the Modified Body Mass Index (mBMI) at Weeks 78 and 156 BMI=weight (kg)/[height (m)^2]. The mBMI is the BMI multiplied by the serum albumin (g/L). Baseline (Baseline is the Baseline of the Previous Study- Study CS2), Weeks 78 and 156
Secondary Change From Baseline in the Body Mass Index (BMI) at Weeks 78 and 156 BMI=weight (kg)/[height (m)^2]. Baseline, Weeks 78 and 156
Secondary Percentage of Participants With Change From Baseline in the Polyneuropathy Disability (PND) Score PND score is defined as I = sensory disturbances in limbs without motor impairment; II = difficulty walking without the need of a walking aid; III = one stick or one crutch required for walking; IV = two sticks or two crutches needed. V = wheelchair required or patient confined to bed. The change from Baseline values have been categorized as: improved, not changed, worsened, and unknown. Percentage of participants with changes from Baseline are presented category-wise in this outcome measure. Only categories with at least one participant with event are reported. Baseline, Weeks 78 and 156 and at the end of each subsequent treatment year (Week 52 of each year)
Secondary Percent Change From Baseline in Global Longitudinal Strain (GLS) by Echocardiogram (ECHO) in the Cardiomyopathy-ECHO (CM-ECHO) Set GLS by ECHO is a measure of cardiac systolic function. Baseline, Weeks 78 and 156
Secondary Percent Change From Baseline in GLS by ECHO in the CS3 ECHO Subgroup GLS by ECHO is a measure of cardiac systolic function. Weeks 78 and 156
Secondary Change From Baseline in Transthyretin (TTR) Level Transthyretin protein concentration in serum was measured. Baseline (Baseline is the Baseline of the Previous Study- Study CS2), Weeks 78 and 156
Secondary Change From Baseline in Retinol Binding Protein 4 (RBP4) Level RBP4 protein concentration in serum was measured. Baseline (Baseline is the Baseline of the Previous Study- Study CS2), Weeks 78 and 156, and at the end of each subsequent treatment year (Week 52 of Years 4 and 5)
Secondary Ctrough: Trough Plasma Concentration of ISIS 420915 Pre-dose on Days 1, 43, 85, 120, 176, 267, 358, 449, 540, 631, 722, 813, 904, 995, 1086, 1268; Days 1359 and 1450 of Year 4; Days 1632, 1723 and 1814 of Year 5
See also
  Status Clinical Trial Phase
Recruiting NCT04893889 - Substudy (NCT04456582): Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Two-dimensional Shear Wave Elastography) in Patients With Amyloidosis and Fabry Disease. N/A
Withdrawn NCT04943302 - Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis Phase 2
Active, not recruiting NCT02909036 - Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. Phase 1
Completed NCT02816476 - Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis Phase 2
Completed NCT01083316 - Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis Phase 2
Completed NCT01527032 - Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis Phase 2
Completed NCT02545907 - A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis Phase 1/Phase 2
Recruiting NCT05263817 - A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis Early Phase 1
Active, not recruiting NCT03201965 - A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis Phase 3
Withdrawn NCT02589860 - Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed NCT02574676 - Quality of Life (QOL) Registry for Patients With AL Amyloidosis
Active, not recruiting NCT02260466 - Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement. N/A
Withdrawn NCT02462213 - Prospective Identification of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging N/A
Recruiting NCT05577819 - Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF N/A
Completed NCT01406314 - SAP Depleter Dose Assessment Study in Patients Phase 1
Not yet recruiting NCT04985734 - Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) in Patients With Idiopathic Peripheral Neuropathy N/A
Active, not recruiting NCT03584022 - Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial N/A
Active, not recruiting NCT05199337 - Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis Phase 1/Phase 2
Active, not recruiting NCT05235269 - A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis Phase 2